Triazolam

Triazolam, also known by the brand name Halcion, is a short-acting benzodiazepine medication primarily prescribed for the short-term treatment of insomnia. It works by enhancing the effect of a neurotransmitter called gamma-aminobutyric acid (GABA) in the brain, which leads to a calming and sedative effect. Triazolam is a Schedule IV controlled substance in the United States, indicating a potential for abuse and dependence.

The typical dosage of triazolam is very low, often in the range of 0.125 to 0.25 milligrams taken before bedtime. Due to its short half-life, it is effective in helping individuals fall asleep and stay asleep for a moderate duration. However, this short duration of action can also lead to early morning awakenings for some users. It is generally recommended for use for no longer than seven to ten consecutive days to minimize the risk of developing tolerance, dependence, or withdrawal symptoms.

Common side effects of triazolam can include drowsiness, dizziness, confusion, impaired coordination, and memory problems (amnesia). It is crucial to avoid operating heavy machinery or driving after taking triazolam. Alcohol and other central nervous system depressants should be avoided as they can significantly increase the sedative effects and potential risks. Gradual tapering of the medication is recommended when discontinuing use to prevent withdrawal symptoms, which can include anxiety, insomnia, tremors, and in severe cases, seizures. Pregnant or breastfeeding individuals should consult with a healthcare professional before using triazolam.